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Speaker’s Corner: Economic Evaluation in 
Prevention and Health Promotion
“Does prevention pay off?” is a question frequently directed 
at health economists, and, as they are economists, they usu-
ally respond “it depends”. The good news is that health eco-
nomic evidence on prevention has steadily increased over the 
past years and a number of interventions have proven favour-
able cost-effectiveness ratios (Wang et al. 2001; Murray et 
al. 2003). The bad news is that this growth has been highly 
selective, and many of the studies lack quality. In a recent 
systematic review we found that the majority of economic 
evaluations that assessed interventions for primary prevention 
of cardiovascular disease are pharmacoeconomic studies of 
clinical prevention that target dyslipidemia and typically refer 
to subjects aged 35–64 years old or seniors (Schwappach et 
al. 2007). Clearly, the rise of economic evaluation studies in 
the last years can predominantly be explained by an increased 
interest of the pharmaceutical industry to prove the cost-ef-
fectiveness of chemoprevention. Studies that evaluated the 
economics of broader health promotion interventions, and in 
particular those addressing the health of children and adoles-
cents are still very rare. This is surprising since advocates of 
health promotion often emphasize the value of so-called “ear-
ly prevention”. Unfortunately, there is yet only little economic 
data to support this notion. Many health economic evaluations 
of prevention are of poor methodological quality and fail to 
provide even basic information necessary for a meaningful 
interpretation of results, for example, documentation of study 
perspective or costing year. However, such weaknesses are 
not unique to the assessment of preventive care, though some 
problems seem more pronounced in this area (Neumann et al 
2000; Schwappach & Boularte 2007). For example, longer 
time periods and rather fragile causal relationships as often 
observed in preventive care lead to higher levels of uncer-
tainty that need to be modelled appropriately. Clearly, stricter 
adherence to health economic guidelines is necessary in the 
evaluation of prevention, care and cure. Leaving these limi-
tations aside for the moment, and overcoming the appeal 
to name and shame specifi c interventions with more or less 
favourable results in terms of cost-effectiveness, what can 
we learn from the economic evaluation of prevention on a 
more general level? Above all, we see that there are several 
methodological aspects in the practice of economic evalua-
tion that bias against preventive care. While often regarded 
as mere “technicalities” many of these practical features re-
fl ect, or mask, how societies value the future health against 
current lives. In particular, the debate about approaches and 
rates of discounting is often perceived as fi nancial arithmetic 
by non-economists. Discounting refers to the concept of ad-
justing future costs and benefi ts occurring at different points 
in time to their present ‘net’ value based on the assumption 
of a positive rate of time preference. If, as an example, an 
intervention costs 1000, 5000, and 10.000 N in the fi rst, sec-
ond and third year respectively, the net value today infl ated 
at an annual 5 % discount rate would be 14.832 N rather than 
16.000 N. If, however, as in prevention, costs (e. g., 10.000 N) 
occur today while benefi ts (e. g., 15 life years saved) occur 
in 20 years, the discounted cost-effectiveness ratio would be 
10.000/5,65 (or 1770 N per life year), rather than the – undis-
counted – 10.000/15 (or 667 N per life year). The assumptions 
underlying discounting procedures are pure value judgments 
aiming to refl ect human time preferences towards immediate 
benefi ts and postponement of costs into the future. In line with 
most guidelines current discounting practice overwhelmingly 
adopts uniform and constant discount rates for both costs and 
health benefi ts, making the cost-effectiveness of prevention 
appear less favourable than curative approaches (Gravelle & 
Smith 2001; Hjelmgren et al. 2001). While there are a number 
of theoretical arguments to support uniform discounting, e. g., 
consistency and avoidance of postponement paradoxes (La-
zaro 2002; Keeler & Cretin 1983), there is also empirical evi-
dence that individual preferences (which are, in fact, the main 
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argument for discounting) depart from uniform non-variable 
discount rates for costs and benefi ts. Findings rather imply a 
need for a discount rate that declines with time (Cairns & Van 
der Pol 1997; Cairns & Van der Pol 2000). Non-uniform, dif-
ferential discounting ‘devalues’ future health benefi ts much 
less than uniform discounting does and prevention would 
thus appear more favourable than it presently seems in health 
economic evaluations. Compared to a constant rate, a declin-
ing discount rate for both costs and benefi ts would support 
public health interventions with costs now and outcomes in 
the distant future, or even next generation, as is the case with 
many preventive interventions. As Severens and Milne argue, 
neither theoretical nor empirical arguments are adequate to 
determine an optimal solution regarding which discounting 
method rate should be used (Severens & Milne 2004). Deci-
sion makers need to discuss whether the current practice of 
using uniform discounting at a constant non-zero discount 
rate, which obviously leads to systematic prioritization of im-
mediate treatment is in concordance with national policies. 
Similar conclusions regarding systematic effects that work 
against prevention can be drawn from the question which fu-
ture costs of related and unrelated illnesses need to be con-
sidered. The current practice of excluding future costs seems 
to bias against preventive interventions, in particular those 
targeted at younger age groups (van Baal et al. 2007). Finally, 
there remains a bunch of questions related to the comparative 
valuation of health effects obtained by preventive versus cura-
tive health care. Here, the core question is whether the cur-
rent practice of estimation of health benefi ts, namely, that the 
benefi t of preventing a health state equals the inverse of being 
in that state, is valid and refl ects social preferences (Schwap-
pach 2002a). There is some evidence that people place more 
value on cure when asked to compare directly the benefi ts of 
prevention and treatment under resource constraints, but fur-
ther research is clearly needed (Ubel et al. 1998; Schwappach 
2002b; Corso et al. 2002). At the end of the day, after unwrap-
ping technicalities, the main question remains as to how we 
value the quality and length of future lives against the quality 
and length of current lives. 
David L.B. Schwappach
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